Novel risk factors for the progression of atherosclerosis such as C-reactive protein (CRP) and adhesion molecules have stimulated much recent interest in the role of inflammation in athero-sclerotic disease. There is also evidence emerging that autoimmunity may have a role in the pathogenesis of atherosclerosis. In this article we explore the evidence for the role of autoimmunity in human atherosclerosis, both in the general population and in the context of the antiphospholipid syndrome. In particular we will focus on several autoantigens, review the evidence for their role in the process of atherosclerosis and the nature of the immune responses.
Vaarala O.Accelerated atherosclerosis in antiphospholipid syndrome. In: Khamashta MA (ed). Hughes' Syndrome. Springer: London , 2000, pp 172-178.
2.
Manzi S , Meilahn E , Rairie J et al. Age specific incidence of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study . Am J Epidemiol1997; 145: 408-415 .
3.
George J , Shoenfeld Y.The anti-phospholipid (Hughes') syndrome: a crossroads of autoimmunity and atherosclerosis . Lupus1997; 6: 559-560 .
4.
Goldstein JL , Ho YK , Basu SK , Brown MS . Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition . Proc Natl Acad Sci USA1979; 76: 3333-3337 .
5.
Brown MS , Goldstein JL . Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis . A Rev Biochem1983; 52: 223-261 .
6.
Henriksen T , Mahoney EM , Steinburg D.Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins . Proc Natl Acad Sci USA1981; 78: 6499-6503 .
7.
Henriksen T , Mahoney EM , Steinburg D.Enhanced macrophage degradation of biologically modified low density lipoprotein . Arteriosclerosis1983; 3: 149-159 .
8.
Hodis HN , Kramsch DM , Avagaro P et al. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-). J Lipid Res1994; 35: 669-677 .
9.
Avogaro P , Bon GB , Cazzolato G.Presence of a modified low density lipoprotein in humans . Arteriosclerosis1988; 8: 79-87 .
10.
Kotani K , Maekawa M , Kanno T , Kondo A , Tada N , Manabe M.Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum . Biochim Biophys Acta1994; 1215: 121-125 .
11.
Itabe H , Yamamoto H , Imanaka T et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody . J Lipid Res1996; 37: 45-53 .
12.
Nagelkerke JF , Havekes L , van Hinsbergh VW , van Berkel TJ . In vivo catabolism of biologically modified LDL . Arteriosclerosis1984; 4: 256-264 .
13.
Palinski W , Yla-Herttuala S , Rosenfeld ME et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein . Arteriosclerosis1990; 10: 325-335 .
14.
Stemme S , Faber B , Holm J , Wiklund O , Witztum J , Hansson G. Tlymphocytes from human atherosclerotic plaques recognise oxidised low density lipoprotein . Proc Natl Acad Sci USA1995; 92: 3893-3897 .
15.
Frostegard J , Ulfgren A , Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage stimulating cytokines . Atherosclerosis1999; 145: 33-43 .
16.
Abdelmouttaleb I , Danchin N , Ilardo C et al. C-reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes . Am Heart J1999; 137: 346-351 .
17.
Haverkate F , Thompson S , Pyke S et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina . Lancet1997; 349: 462-466 .
18.
Ridker P , Cushman M , Stampfer M , Tracy R , Hennekens C.Inflammmation, aspirin, and the risk of cardiovascular disease in apparently healthy men . New Engl J Med1997; 336: 973-979 .
19.
Peter K , Nawroth P , Conradt C et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin and thrombomodulin . Atheroscler Thromb Vasc Biol1997; 17: 505-512 .
20.
Blann AD , McCollum C.Circulating endothelial cell/leucocyte adhesion molecules in atherosclerosis . Thromb Haemost1994; 72: 151-154 .
21.
Salonen J , Yla-Herttuala S , Yamamoto R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis . Lancet1992; 339: 883-887 .
22.
Purunen M , Manttari M , Manninen Vesa et al. Antibodies against oxidised low density lipoprotein predicting myocardial infarction . Arch Intern Med1994; 154: 2605-2609 .
23.
Jonassen L , Holm J , Skalli O , Bondjers G , Hansseon G.Regional accumulation of T-cells, macrophages and smooth muscle cells in the human atherosclerotic plaque . Arteriosclerosis1986; 6: 131-138 .
24.
Seifert PS , Hansson G.Complement receptors and regulatory proteins in human atherosclerotic lesions . Arteriosclerosis1989; 9: 802-811 .
25.
Hollander W , Colombo M , Kirkpatrick B , Paddock J.Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3-complement component, alpha 1-antitrypsin and alpha 2-macroglobulin . Atherosclerosis1979; 34: 391-405 .
26.
Hamanaka R , Kohno K , Seguchi T et al. Induction of low density lipoprotein receptor and a transcription factor SP-1 by tumor necrosis factor in human microvascular endothelial cells . J Biol Chem1992; 267: 13160-13165 .
Stopeck A , Nicholson A , Mancini F , Hajjar D.Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells . J Biol Chem1993; 268: 17489-17494 .
29.
Palinski W , Miller E , Witztum JL . Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis . Proc Natl Acad Sci USA1995; 92: 821-825 .
30.
George J , Afek A , Gilburd B , Levy Y , Levkovitz H , Shaish A , Goldberg I , Kopolovic Y , Wick G , Shonfield Y , Harats D.Hyper-immunization of ApoE deficient mice with homologous oxLDL suppresses early atherogenesis . Atherosclerosis1998; 138: 147-152 .
31.
Wilson W , Gharavi A , Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome . Arthritis Rheum1999; 42: 1309-1311 .
32.
George J , Harats D , Gilburd B et al. Immunolocalisation of b2-Glycoprotein I (Apolipoprotein H) to human atherosclerotic plaques . Circulation1999; 99: 2227-2230 .
33.
George J , Afek A , Gilburd B et al. Induction of early atherosclerosis in LDL deficient mice immunized with b2-glycoprotein I . Circulation1998; 98: 1108-1115 .
34.
Afek A , George J , Schonfeld Y , Gilburd B , Levy Y , Keren P , Shaish A , Janakovic Z , Harats D.Enhanced atherosclerosis in ApoE deficient mice by immunization with b2-glycoprotein 1 . Pathobiology1999; 67: 19-25 .
35.
Hasunuma Y , Matsuura E , Makita Z , Katahira T , Nishi S , Koike T.Involvement of B2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages . Clin Exp Immunol1997; 107: 569-573 .
36.
Vaarala O , Alfthan G , Jauhiainen M , Leirisalo-Repo M , Aho K , Palosuo T.Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus . Lancet1993; 341: 923-925 .
37.
Simantov R , LaSala JM , Lo SK et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies . J Clin Invest1995; 96: 2211-2219 .
38.
George J , Blank M , Levy Y et al. Differential effects of anti-B2 glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome . Circulation1998; 97: 900-906 .
39.
Ross R.Mechanisms of disease: atherosclerosis — an inflammatory disease . New Engl J Med1999; 340: 115-126 .
40.
George J , Blank M , Hojnik M , Bar-Meir E , Koike T , Matsuura E , Lorber M , Aviram M , Schonfeld Y.Oxidised low density lipo-protein (oxLDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome . Clin Exp Immunol1997; 108: 227-233 .
41.
Berg K , Dahlen G , Frick M. Lp(a)lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease . Clin Genet1974; 6: 230-235 .
42.
Dahlen G , Guyton J , Attar M , Farmer J , Kautz J , Gotto A.Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary heart disease documented by angiography . Circulation1986; 74: 758-765 .
43.
Scanu AM , Fless G. Lipoprotein(a) . Heterogeneity and biological relevance . J Clin Invest1990; 85: 1709-1715 .
44.
Nagayama M , Shinohara Y , Nagayama T.Lipoprotein(a) and ischemic cerebrovascular disease in young adults . Stroke1994; 25: 74-78 .
45.
Rath M , Niendorf A , Reblin T , Dietel M , Krebber H , Beisiegel U.Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients . Arteriosclerosis1989; 9: 579-592 .
46.
Pepin J , O'Neil J , Hoff H.Quantification of apo(a) and apoB in human atherosclerotic lesions . J Lipid Res1991; 32: 317-327 .
47.
Sattler W , Kostner G , Esterbauer H.Oxidation of lipoprotein(a). A comparison with low density lipoproteins . Biochim Biophys Acta1991; 1081: 65-71 .
48.
Naruszewicz M , Selinger E , Davignon J.Oxidative modification of lipoprotein(a) and the effect of beta-carotene . Metabolism1992; 41: 1215-1224 .
49.
Haberland ME , Fless G , Scanu A , Fogelman A.Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages . J Biol Chem1992; 267: 4143-4151 .
50.
Romero FI , Atsuya T , Tinahones FJ et al. Autoantibodies against malondialdehyde-modified lipoprotein(a) in the antiphospholipid syndrome . Arthritis Rheum1999; 42: 2606-2611 .
51.
Romero FI , Khamashta MA , Atsumi T et al. Autoantibodies against oxidised liapoprotein(a) in systemic lupus erythematosus (SLE). Arthitis Rheum1999; 42: S147-S147 .
52.
Kochl S , Fresser F , Lobentanz E , Baier G , Uttermann G.Novel interaction of apolipoprotein(a) with b2 glycoprotein I mediated by the kringle IV domain . Blood1997; 90: 1482-1489 .
53.
Xu Q , Schett G , Seitz C , Gupta R , Wick G.Surface staining and cytotoxic activity of heat shock protein 60 antibody on stressed aortic endothelial cells . Circulation Res1994; 75: 1078-1085 .
54.
Xu Q , Kiechl S , Mayr M.Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow up study . Circulation1999; 14(100(11)): 1169-1174 .
55.
Danesh J , Collins R , Peto R.Chronic infections and coronary heart disease: is there a link?Lancet1997; 350: 430-436 .
56.
Metzler B , Schett G , Kleindeinst R et al. Epitope specificity of anti-heat-shock protein 60=65 serum antibodies in atherosclerosis . Arterioscler Thromb Vasc Biol1997; l7: 536-541 .
57.
George J , Shoenfeld Y , Afek A , Gilburd B , Keren P , Shaish A , Y. Kopolovic , G Wick , Harats D.Enhanced fatty streak formation in C57BL=6J mice by immunization with heat shock protein 65 . Arteriscler Thromb Vasc Biol1999; 19: 505-510 .
58.
Xu Q , Dietrich H , Steiner H et al. Induction of atherosclerosis in normocholesterolemic rabbits by immunization with heat-shock protein 65 . Arterioscler Thromb1992; 12: 789-799 .
